Curated News
By: NewsRamp Editorial Staff
February 24, 2026

Soligenix CEO to Present at BIO Summit, Showcasing Rare Disease and Vaccine Pipeline

Original Source

TLDR

  • Soligenix's CEO presentation at the BIO Investment Summit offers investors early insight into the company's late-stage biopharmaceutical pipeline for rare diseases.
  • Soligenix develops HyBryte for CTCL using photodynamic therapy and ThermoVax heat stabilization for vaccines, with regulatory approvals sought after Phase 3 studies.
  • Soligenix's treatments for rare diseases and vaccines for threats like COVID-19 address unmet medical needs and improve public health worldwide.
  • Soligenix uses visible light therapy for cancer and heat-stabilized vaccines, presenting at a Miami biotech summit focused on growth-stage companies.

Impact - Why it Matters

This news matters because Soligenix's work addresses critical gaps in healthcare, particularly for rare diseases and public health threats. Their advancements in treatments like HyBryte™ for cutaneous T-cell lymphoma could offer new hope for patients with limited options, potentially improving quality of life and survival rates. In the Public Health Solutions segment, vaccine candidates for ricin, filoviruses, and COVID-19 contribute to global biodefense and pandemic preparedness, enhancing societal resilience against emerging infectious diseases and bioterrorism risks. For investors, Soligenix's progress and government-backed funding signal growth potential in the biotech sector, while the broader public benefits from innovations that strengthen medical and public health infrastructure. The company's focus on unmet needs aligns with increasing demand for specialized therapies and vaccines, making their developments relevant to healthcare systems, policymakers, and communities worldwide.

Summary

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, announced that its President and CEO, Christopher J. Schaber, Ph.D., will present at the BIO Investment & Growth Summit on March 2nd in Miami Beach, Florida. This event, focused on growth-stage biotechnology firms, provides a platform for Soligenix to highlight its pipeline to investors and industry peers. The company's presentation is part of broader efforts to engage with the investment community, with additional details available through the conference website and a full press release accessible via the provided link.

The company operates through two key business segments: Specialized BioTherapeutics and Public Health Solutions. In the Specialized BioTherapeutics segment, Soligenix is advancing HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), which has completed a second Phase 3 study and is moving toward potential global commercialization. This segment also includes development programs for synthetic hypericin (SGX302) in psoriasis, dusquetide (SGX942) for inflammatory diseases like oral mucositis, and SGX945 for Behçet’s Disease. These initiatives target rare diseases with unmet medical needs, positioning Soligenix as a key player in niche therapeutic areas.

In the Public Health Solutions segment, Soligenix focuses on vaccine candidates, including RiVax® for ricin toxin, filovirus vaccines for threats like Marburg and Ebola, and CiVax™ for COVID-19 prevention. These programs leverage the company's proprietary ThermoVax® heat stabilization technology and have received significant government funding from agencies such as the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). This support underscores the strategic importance of Soligenix's work in public health preparedness and biodefense.

The news release was distributed by BioMedWire (“BMW”), a specialized communications platform within the Dynamic Brand Portfolio @ IBN, which provides extensive media and investor outreach services. BioMedWire enhances visibility for biotechnology and biomedical companies through wire solutions, editorial syndication, and social media distribution, helping firms like Soligenix reach a broad audience of investors and stakeholders. This partnership highlights the role of effective communication in advancing biotech innovations and engaging the public and investment communities.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix CEO to Present at BIO Summit, Showcasing Rare Disease and Vaccine Pipeline

blockchain registration record for this content.